15 mg of semaglutide | Clinician-Reviewed Peptide Therapy Photo Illustration of the new

Food and Drug Administration (FDA) for treating obesity and type 2 diabetes, semaglutide is rapidly gaining recognition as a leading medication in diabetes treatment

Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: A systematic review and meta-analysis

When blood glucose exceeds the renal threshold (typically around 180 mg/dL, though this varies between individuals), glucose appears in urine, creating an osmotic diuresis that increases urine volume

However, this drug has become the star of a weight loss fad, resulting in an exponential increase in demand